{"product_id":"biolegend-320102","title":"Biolegend, 320102, Purified anti-human FOXP3 Antibody, 100μg","description":"\u003cp\u003eFOXP3 is a 50-55 kD transcription factor, also known as Forkhead box protein P3, Scurfin, JM2, or IPEX. It is proposed to be a master regulatory gene and more specific marker of T regulatory cells than most cell surface markers (such as CD4 and CD25). Transduced expression of FOXP3 in CD4 + \/CD25 - cells has been shown to induce GITR, CD103, and CTLA4 and impart a T regulatory cell phenotype. FOXP3 is mutated in X-linked autoimmunity-allergic dysregulation syndrome (XLAAD or IPEX) in humans and in \"scurfy\" mice. Overexpression of FOXP3 has been shown to lead to a hypoactive immune state suggesting that this transcriptional factor is a central regulator of T cell activity. In human, unlike in mouse, two isoforms of FOXP3 have been reported: one (FOXP3) corresponding to the canonical full-length sequence; the other (FOXP3 δ2) lacking exon 2. The 206D antibody recognizes human FOXP3 epitope in the region of amino acids 105-235.\u003cbr\u003e\n100μg\u003cbr\u003e\nVerified Reactivity: Human\u003cbr\u003e\nReported Reactivity: Baboon, Cynomolgus, Rhesus, Pigtailed Macaque\u003cbr\u003e\nAntibody Type: Monoclonal\u003cbr\u003e\nHost Species: Mouse\u003cbr\u003e\nImmunogen: Full-length FOXP3 protein\u003cbr\u003e\nFormulation: This antibody is provided in phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.\u003cbr\u003e\nPreparation: The antibody was purified by affinity chromatography.\u003cbr\u003e\nConcentration: 0.5 mg\/ml\u003cbr\u003e\nStorage \u0026amp; Handling: The antibody solution should be stored undiluted between 2°C and 8°C.\u003cbr\u003e\nApplication: WB - Quality tested ICFC, IHC-F, IHC-P - Reported in the literature, not verified in house\u003cbr\u003e\nRecommended Usage: Each lot of this antibody is quality control tested by immunofluorescent intracellular staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.5 µg per 106 cells in 100 µl volume. For Western blotting, the suggested working dilution(s) is ≤ 5.0 µg\/ml in antibody dilution buffer. It is recommended that the reagent be titrated for optimal performance for each application.\u003cbr\u003e\nApplication Notes: Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen sections1 and formalin-fixed paraffin-embedded sections1,8,19-20, and Western blotting1. The binding of 206D to FOXP3 can be partially blocked by 259D, but 206D does not show significant blocking effect on 259D binding. NOTE: For flow cytometric staining with this clone, True-Nuclear™ Transcription Factor Buffer Set (Cat. No. 424401) offers improved staining and is highly recommended.\u003cbr\u003e\nApplication References(PubMed link indicates BioLegend citation): Roncador G, et al. 2005. Eur. J. Immunol. 35:1681.(IHC) Yang ZZ, et al. 2006. Blood 107:3639. Liu W, et al. 2006. J. Exp. Med. 203:1701.PubMed Bollyky PL, et al. 2007. J. Immunol. 179:744. Bell MP, et al. 2007. J. Immunol. 179:1893. Tran DQ, et al. 2007. Blood doi:10.1182\/blood-2007-06-094656. PubMed Gao Q,et al.2007.J Clin Oncol.25:2586.(IHC) PubMed Pillai V,et al. 2008. Blood 111:463. PubMed Zheng Y, et al. 2008. J. Immunol. 181:1683. PubMed Zonios DI, et al. 2008.Blood112:287. PubMed Kavanagh B, et al. 2008. Blood. PubMed Nevala WK, et al. 2009. Clin Cancer Res. 15:1931. PubMed Grant J, et al. 2009. Cytometry B Clin Cytom. 76:69. PubMed Nigam P, et al. 2010. J. Immunol. 184:1690. PubMed Kmieciak M, et al. 2009. J. Transl. Med. 7:89. (ICFC) PubMed Hartigan-O'Connor DJ,et al.2007.J Exp Med.204:2679. PubMed Raghaven S, et al. 2009. Ann Rheum Dis. 68:1908. PubMed Hodi FS, et al. 2014. Cancer Immunol Res. 2:632.(IHC) PubMed Sziros E, et al. 2015. Clin Cancer Res. 21:2840.(IHC) PubMed\u003cbr\u003e\nProduct Citations: Chen S, et al. 2020. Transl Lung Cancer Res. 1.404861111. PubMed Martini R, et al. 2022. Cancer Discov. 12:2530. PubMed Gregory S, et al. 2023. Am J Cancer Res. 12:5564. PubMed Kavanagh B, et al. 2008. Blood. 112:1175. PubMed Richardson LG, et al. 2020. Oncoimmunology. 9:1806662. PubMed Riquelme E et al. 2019. Cell. 178(4):795-806 . PubMed Parra E,et al. 2017. Sci Rep.. 10.1038\/s41598-017-13942-8. PubMed Chen P, et al. 2021. J Immunother Cancer. 9:. PubMed Haymaker C, et al. 2021. Cancer Discov. 11:1996. PubMed Nugent JL, et al. 2021. iScience. 24:103421. PubMed Karandikar V 2008. Blood. 111:463. PubMed Werneburg S, et al. 2020. Immunity. 52(1):167-182.e7.. PubMed Lin JR et al. 2018. eLife. 7 pii: e31657. PubMed Mitra A, et al. 2020. Nat Commun. 11:1839. PubMed Derks S, et al. 2020. Ann Oncol. 31:1011. PubMed Li Y, et al. 2019. Front Immunol. 0.460416667. PubMed Vence L, et al. 2019. Clin Cancer Res. 25:6501. PubMed Liu X, et al. 2022. STAR Protoc. 3:101310. PubMed Burlingame EA, et al. 2021. Cell Rep Methods. 1:. PubMed Boucher Y, et al. 2021. NPJ Precis Oncol. 5:62. PubMed de Groot J, et al. 2020. Neuro Oncol. 539:22. PubMed Helmink BA, et al. 2020. Nature. 577:549. PubMed Li W, et al. 2018. BMC Cancer. 1.589583333. PubMed Xie S, et al. 2020. Ann Transl Med. 1.384027778. PubMed Zeigler-Johnson C, et al. 2016. PLoS One. 11: 0159109. PubMed Gao Q, et al. 2007. J Clinical Oncololgy. 25:2586. PubMed Donnelly C, et al. 2018. Sci Rep. 0.625. PubMed Msaouel P, et al. 2020. Cancer Cell. 720:37. PubMed Hodi F, et al. 2014. Cancer Immunol Res. 2:632. PubMed Zsiros E, et al. 2015. Clin Cancer Res. 21:2840. PubMed Sadigh S, et al. 2020. Am J Clin Pathol. 387:153. PubMed Wang H, et al. 2021. Onco Targets Ther. 14:2953. PubMed Luoma AM, et al. 2020. Cell. 182(3):655-671.e22. PubMed Amaria RN, et al. 2018. Nat Med. 24:1649. PubMed Blessin NC, et al. 2019. Dis Markers. 2019:5160565. PubMed Durgin JS, et al. 2021. Front Oncol. 11:669071. PubMed Jiang M, et al. 2021. J Immunother Cancer. 9:. PubMed Zonios D, et al. 2008. Blood. 112:287. PubMed\u003cbr\u003e\nRRID: AB_430880 (BioLegend Cat. No. 320101) AB_430881 (BioLegend Cat. No. 320102)\u003cbr\u003e\nStructure: Forkhead\/winged-helix transcription factor family, approximately 50 kD, contains zinc finger and forkhead domains\u003cbr\u003e\nDistribution: Nuclear; expressed in T regulatory cells\u003cbr\u003e\nFunction: Transcription factor proposed to be a master regulatory gene in T regulatory cell development and a critical factor for immune homeostasis\u003cbr\u003e\nInteraction: Interacts with DNA\u003cbr\u003e\nCell Type: Tregs\u003cbr\u003e\nBiology Area: Cell Biology, Immunology, Transcription Factors\u003cbr\u003e\nMolecular Family: Nuclear Markers\u003cbr\u003e\nAntigen References: 1. Hori S, et al. 2003. Science 299:1057. 2. Gandhi R, et al. 2010. Nat. Immunol. 11:846.\u003cbr\u003e\nRegulation: FOXP3 is present at high levels in T regulatory cells, it can also be induced by T cell activation.\u003cbr\u003e\nGene ID: 50943\u003cbr\u003e\nUniProt: View information about FOXP3 on UniProt.org\u003cbr\u003e\nClone: 206D\u003cbr\u003e\nRegulatory Status: RUO\u003cbr\u003e\nOther Names: Forkhead box protein P3, Scurfin, JM2, IPEX, Zinc finger protein JM2\u003cbr\u003e\nIsotype: Mouse IgG1, κ\u003cbr\u003e\nQ: Can I stain whole blood with anti-FOXP3 using your Foxp3 staining kit?\u003cbr\u003e\nA: It is not recommended. It is best to use PBMCs for this testing.\u003cbr\u003e\nQ: Can FOXP3 be costained with cytokines?\u003cbr\u003e\nA: The larger holes created by the nuclear permeabilization required for FOXP3 may allow cytokines to leak out of the cell, making it harder to detect lowly-expressed cytokines. You may have to use a control where the cells are only permeabilized through the cell membrane.\u003c\/p\u003e","brand":"Biolegend","offers":[{"title":"Default Title","offer_id":46860867961001,"sku":"320102","price":0.99,"currency_code":"USD","in_stock":true}],"url":"https:\/\/iright.com\/es\/products\/biolegend-320102","provider":"Iright","version":"1.0","type":"link"}